{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:15:01Z","timestamp":1784304901532,"version":"3.55.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100022274","name":"Daiichi Sankyo Europe GmbH","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100022274","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100015739","name":"Bayer Vital GmbH","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015739","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Bristol-Myers Squibb\/Pfizer"},{"name":"Boehringer-Ingelheim Pharma GmbH &Co.KG"},{"DOI":"10.13039\/501100022274","name":"Daiichi Sankyo Europe GmbH","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100022274","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100015739","name":"Bayer Vital GmbH","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015739","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Bristol-Myers Squibb\/Pfizer"},{"name":"Boehringer-Ingelheim Pharma GmbH &Co.KG"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anticoagulation with vitamin K antagonists and non-vitamin K antagonists oral anticoagulants (NOAC) is effective in stroke prevention in patients with atrial fibrillation. However, anticoagulation also poses a major challenge for emergency treatment of patients suffering ischaemic stroke or intracerebral haemorrhage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>The registry RASUNOA-prime is designed to describe current patterns of emergency management, clinical course and outcome of patients with atrial fibrillation experiencing an acute ischaemic stroke or intracerebral haemorrhage under different anticoagulation schemes prior to stroke (NOAC, vitamin K antagonists or no anticoagulation).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and design<\/jats:title>\n                    <jats:p>RASUNOA-prime (ClinicalTrials.gov, NCT02533960) is a prospective, investigator-initiated, multicentre, observational cohort study aiming to recruit 3000 patients with acute ischaemic stroke and atrial fibrillation, and 1000 patients with acute intracerebral haemorrhage and atrial fibrillation with different anticoagulation schemes pre-stroke. It is a non-interventional triple-armed study aiming at a balanced inclusion of ischaemic stroke and intracerebral haemorrhage patients according to the different anticoagulation schemes. Patients will be followed up for clinical course, management and outcome up to three months after the event. Findings in ischaemic stroke and intracerebral haemorrhage patients on NOAC will be compared with patients taking vitamin K antagonists or no anticoagulant pre-stroke.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study outcomes<\/jats:title>\n                    <jats:p>Primary endpoint for ischaemic stroke patients: occurrence of symptomatic intracerebral haemorrhage, for intracerebral haemorrhage patients: occurrence of secondary haematoma expansion. Secondary endpoints include assessment of coagulation, use of thrombolysis and\/or mechanical thrombectomy, occurrence of complications, implementation of secondary prevention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Describing the current patterns of early management as well as outcome of stroke patients with atrial fibrillation will help guide physicians to develop recommendations for emergency treatment of stroke patients under different anticoagulation schemes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/2396987318812644","type":"journal-article","created":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T03:47:13Z","timestamp":1545018433000},"page":"181-188","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":13,"title":["Rationale and design of the Registry of Acute Stroke Under Novel Oral Anticoagulants-prime (RASUNOA-prime)"],"prefix":"10.1093","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2731-9017","authenticated-orcid":false,"given":"Kirsten","family":"Haas","sequence":"first","affiliation":[{"name":"Institute of Clinical Epidemiology and Biometry, University of W\u00fcrzburg, W\u00fcrzburg, Germany 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan C","family":"Purrucker","sequence":"additional","affiliation":[{"name":"Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timolaos","family":"Rizos","sequence":"additional","affiliation":[{"name":"Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter U","family":"Heuschmann","sequence":"additional","affiliation":[{"name":"Institute of Clinical Epidemiology and Biometry, University of W\u00fcrzburg, W\u00fcrzburg, Germany 1"},{"name":"Comprehensive Heart Failure Centre, University of W\u00fcrzburg, W\u00fcrzburg, Germany 3"},{"name":"Clinical Trial Center, University Hospital W\u00fcrzburg, W\u00fcrzburg, Germany 4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Veltkamp","sequence":"additional","affiliation":[{"name":"Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany 2"},{"name":"Department of Neurology, Alfried Krupp Hospital, Essen, Germany 5"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,6,1]]},"reference":[{"key":"2026012113195796500_bibr1-2396987318812644","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"2026012113195796500_bibr2-2396987318812644","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000371353","article-title":"Time trends in incidence of pathological and etiological stroke subtypes during 16 years: the Erlangen Stroke project","volume":"44","author":"Kolominsky-Rabas","year":"2015","journal-title":"Neuroepidemiology"},{"key":"2026012113195796500_bibr3-2396987318812644","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"2026012113195796500_bibr4-2396987318812644","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"2026012113195796500_bibr5-2396987318812644","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"2026012113195796500_bibr6-2396987318812644","doi-asserted-by":"crossref","first-page":"31477","DOI":"10.1038\/srep31477","article-title":"Non-vitamin K antagonist oral anticoagulation usage according to age among patients with atrial fibrillation: temporal trends 2011\u20132015 in Denmark","volume":"6","author":"Staerk","year":"2016","journal-title":"Sci Rep"},{"key":"2026012113195796500_bibr7-2396987318812644","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S1474-4422(13)70101-7","article-title":"Treatment of acute ischaemic stroke with thrombolysis or thrombectomy in patients receiving anti-thrombotic treatment","volume":"12","author":"Diener","year":"2013","journal-title":"Lancet Neurol"},{"key":"2026012113195796500_bibr8-2396987318812644","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1161\/STROKEAHA.116.013343","article-title":"Anticoagulant-associated intracranial hemorrhage in the era of reversal agents","volume":"48","author":"Steiner","year":"2017","journal-title":"Stroke"},{"key":"2026012113195796500_bibr9-2396987318812644","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1177\/1747493016659671","article-title":"Measuring non-vitamin K antagonist oral anticoagulant levels: when is it appropriate and which methods should be used?","volume":"11","author":"Drouet","year":"2016","journal-title":"Int J Stroke"},{"key":"2026012113195796500_bibr10-2396987318812644","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal \u2013 full cohort analysis","volume":"377","author":"Pollack","year":"2017","journal-title":"N Engl J Med"},{"key":"2026012113195796500_bibr11-2396987318812644","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s11910-017-0783-5","article-title":"Management of spontaneous intracerebral hemorrhage","volume":"17","author":"Veltkamp","year":"2017","journal-title":"Curr Neurol Neurosci Rep"},{"key":"2026012113195796500_bibr12-2396987318812644","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1007\/s00115-015-4395-5","article-title":"Aktualisierte zertifizierungskriterien f\u00fcr regionale und \u00fcberregionale stroke-units in Deutschland","volume":"86","author":"Nabavi","year":"2015","journal-title":"Nervenarzt"},{"key":"2026012113195796500_bibr13-2396987318812644","volume-title":"Clinical epidemiology: principles, methods, and applications for clinical research","author":"Grobbee","year":"2009"},{"key":"2026012113195796500_bibr14-2396987318812644","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/STROKEAHA.111.623033","article-title":"Improved prediction of poor outcome after thrombolysis using conservative definitions of symptomatic hemorrhage","volume":"43","author":"Gumbinger","year":"2012","journal-title":"Stroke"},{"key":"2026012113195796500_bibr15-2396987318812644","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1212\/WNL.0b013e3182143317","article-title":"Defining hematoma expansion in intracerebral hemorrhage: relationship with patient outcomes","volume":"76","author":"Dowlatshahi","year":"2011","journal-title":"Neurology"},{"key":"2026012113195796500_bibr16-2396987318812644","first-page":"759","article-title":"The quality of acute stroke care \u2013 an analysis of evidence-based indicators in 260 000 patients","volume":"111","author":"Wiedmann","year":"2014","journal-title":"Deutsches Arzteblatt Int"},{"key":"2026012113195796500_bibr17-2396987318812644","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1474-4422(10)70313-6","article-title":"Neurological complications of acute ischaemic stroke","volume":"10","author":"Balami","year":"2011","journal-title":"Lancet Neurol"},{"key":"2026012113195796500_bibr18-2396987318812644","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1056\/NEJMoa0707534","article-title":"Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage","volume":"358","author":"Mayer","year":"2008","journal-title":"N Engl J Med"},{"key":"2026012113195796500_bibr19-2396987318812644","first-page":"2249","article-title":"Early hemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome","volume":"39","author":"Paciaroni","year":"2008","journal-title":"Results Prospective Multicenter Study"},{"key":"2026012113195796500_bibr20-2396987318812644","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1161\/STR.0000000000000158","article-title":"Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"49","author":"Powers","year":"2018","journal-title":"Stroke"},{"key":"2026012113195796500_bibr21-2396987318812644","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1159\/000131083","article-title":"Guidelines for management of ischaemic stroke and transient ischaemic attack 2008","volume":"25","year":"2008","journal-title":"Cerebrovasc Dis (Basel, Switzerland)"},{"key":"2026012113195796500_bibr22-2396987318812644","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/2396987317699144","article-title":"Recommendations from the ESO-Karolinska Stroke Update Conference, Stockholm 13\u201315 November 2016","volume":"2","author":"Ahmed","year":"2017","journal-title":"Eur Stroke J"},{"key":"2026012113195796500_bibr23-2396987318812644","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1001\/jama.2012.6756","article-title":"Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator","volume":"307","author":"Xian","year":"2012","journal-title":"JAMA"},{"key":"2026012113195796500_bibr24-2396987318812644","doi-asserted-by":"crossref","first-page":"67","DOI":"10.5853\/jos.2016.00542","article-title":"Haemorrhagic transformation after ischaemic stroke in patients taking non-vitamin K antagonist oral anticoagulants","volume":"19","author":"Purrucker","year":"2017","journal-title":"J Stroke"},{"key":"2026012113195796500_bibr25-2396987318812644","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s12028-010-9443-1","article-title":"Fast point-of-care coagulometer guided reversal of oral anticoagulation at the bedside hastens management of acute subdural hemorrhage","volume":"13","author":"Rizos","year":"2010","journal-title":"Neurocrit Care"},{"key":"2026012113195796500_bibr26-2396987318812644","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13054-017-1619-z","article-title":"Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants","volume":"21","author":"Ebner","year":"2017","journal-title":"Critical Care"},{"key":"2026012113195796500_bibr27-2396987318812644","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1161\/STROKEAHA.116.014963","article-title":"Coagulation testing in acute ischemic stroke patients taking non-vitamin K antagonist oral anticoagulants","volume":"48","author":"Purrucker","year":"2017","journal-title":"Stroke"},{"key":"2026012113195796500_bibr28-2396987318812644","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1212\/01.WNL.0000138428.40673.83","article-title":"Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage","volume":"63","author":"Flibotte","year":"2004","journal-title":"Neurology"},{"key":"2026012113195796500_bibr29-2396987318812644","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S1474-4422(16)00110-1","article-title":"Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial","volume":"15","author":"Steiner","year":"2016","journal-title":"Lancet Neurol"},{"key":"2026012113195796500_bibr30-2396987318812644","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1212\/WNL.0000000000003886","article-title":"Outcome of intracerebral hemorrhage associated with different oral anticoagulants","volume":"88","author":"Wilson","year":"2017","journal-title":"Neurology"},{"key":"2026012113195796500_bibr31-2396987318812644","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1001\/jamaneurol.2015.3682","article-title":"Early clinical and radiological course, management, and outcome of intracerebral hemorrhage related to new oral anticoagulants","volume":"73","author":"Purrucker","year":"2016","journal-title":"JAMA Neurol"},{"key":"2026012113195796500_bibr32-2396987318812644","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1093\/europace\/eux087","article-title":"Non-vitamin K-dependent oral anticoagulants have a positive impact on ischaemic stroke severity in patients with atrial fibrillation","volume":"20","author":"Hellwig","year":"2018","journal-title":"Europace"}],"container-title":["European Stroke Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2396987318812644","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2396987318812644","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/esj\/article\/4\/2\/181\/8275863","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/esj\/article\/4\/2\/181\/8275863","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:23:50Z","timestamp":1769019830000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/esj\/article\/4\/2\/181\/8275863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,1]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,6,1]]}},"URL":"https:\/\/doi.org\/10.1177\/2396987318812644","relation":{},"ISSN":["2396-9873","2396-9881"],"issn-type":[{"value":"2396-9873","type":"print"},{"value":"2396-9881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,6,1]]},"published":{"date-parts":[[2019,6,1]]}}}